| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Embolization, Therapeutic | 16 | 2024 | 226 | 4.060 |
Why?
|
| Hematoma, Subdural, Chronic | 7 | 2024 | 9 | 3.080 |
Why?
|
| Thrombectomy | 18 | 2024 | 104 | 2.880 |
Why?
|
| Bone Screws | 8 | 2015 | 51 | 2.200 |
Why?
|
| Atlanto-Axial Joint | 8 | 2015 | 21 | 1.870 |
Why?
|
| Meningeal Arteries | 8 | 2024 | 11 | 1.850 |
Why?
|
| Stroke | 18 | 2024 | 958 | 1.760 |
Why?
|
| Tinnitus | 2 | 2023 | 19 | 1.660 |
Why?
|
| Intracranial Aneurysm | 8 | 2022 | 93 | 1.480 |
Why?
|
| Endovascular Procedures | 11 | 2024 | 734 | 1.320 |
Why?
|
| Neurosurgical Procedures | 6 | 2020 | 299 | 1.170 |
Why?
|
| Treatment Outcome | 46 | 2024 | 12169 | 1.080 |
Why?
|
| Cranial Sinuses | 2 | 2023 | 12 | 1.040 |
Why?
|
| Stents | 11 | 2024 | 876 | 1.040 |
Why?
|
| Magnesium Sulfate | 1 | 2024 | 50 | 0.930 |
Why?
|
| Cervical Vertebrae | 2 | 2015 | 107 | 0.910 |
Why?
|
| Neuroprotective Agents | 1 | 2024 | 150 | 0.850 |
Why?
|
| Drainage | 2 | 2016 | 257 | 0.850 |
Why?
|
| Cerebral Revascularization | 3 | 2023 | 21 | 0.830 |
Why?
|
| Constriction, Pathologic | 7 | 2023 | 240 | 0.820 |
Why?
|
| Spinal Fusion | 7 | 2018 | 107 | 0.720 |
Why?
|
| Brain Ischemia | 5 | 2023 | 258 | 0.700 |
Why?
|
| Aged | 35 | 2024 | 19194 | 0.650 |
Why?
|
| Retrospective Studies | 36 | 2024 | 16068 | 0.640 |
Why?
|
| Craniotomy | 3 | 2016 | 108 | 0.640 |
Why?
|
| Middle Aged | 40 | 2024 | 26087 | 0.640 |
Why?
|
| Cervical Atlas | 2 | 2016 | 8 | 0.640 |
Why?
|
| Aged, 80 and over | 21 | 2024 | 6392 | 0.630 |
Why?
|
| Joint Instability | 3 | 2013 | 42 | 0.620 |
Why?
|
| Cerebral Hemorrhage | 4 | 2023 | 144 | 0.610 |
Why?
|
| Vertebral Artery | 3 | 2014 | 24 | 0.600 |
Why?
|
| Humans | 78 | 2024 | 123258 | 0.580 |
Why?
|
| Angioplasty | 4 | 2024 | 85 | 0.580 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2022 | 389 | 0.550 |
Why?
|
| Propensity Score | 4 | 2024 | 212 | 0.530 |
Why?
|
| Neurosurgery | 2 | 2014 | 76 | 0.530 |
Why?
|
| Arthrodesis | 2 | 2015 | 14 | 0.520 |
Why?
|
| Hematoma, Subdural | 1 | 2016 | 20 | 0.520 |
Why?
|
| Tranexamic Acid | 1 | 2016 | 19 | 0.520 |
Why?
|
| Antifibrinolytic Agents | 1 | 2016 | 33 | 0.510 |
Why?
|
| Anticoagulants | 3 | 2023 | 580 | 0.470 |
Why?
|
| Orthopedic Procedures | 1 | 2015 | 68 | 0.460 |
Why?
|
| Male | 43 | 2024 | 60336 | 0.430 |
Why?
|
| Spinal Injuries | 1 | 2013 | 29 | 0.430 |
Why?
|
| Aneurysm, Ruptured | 2 | 2015 | 36 | 0.430 |
Why?
|
| Female | 44 | 2024 | 65619 | 0.430 |
Why?
|
| Arachnoid | 2 | 2023 | 8 | 0.430 |
Why?
|
| Carotid Artery Diseases | 1 | 2014 | 147 | 0.420 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2024 | 2058 | 0.420 |
Why?
|
| Prostheses and Implants | 1 | 2014 | 150 | 0.410 |
Why?
|
| Betacoronavirus | 3 | 2020 | 285 | 0.400 |
Why?
|
| Spinal Cord | 2 | 2021 | 304 | 0.390 |
Why?
|
| Heparin | 1 | 2013 | 227 | 0.390 |
Why?
|
| Arteries | 1 | 2012 | 222 | 0.370 |
Why?
|
| Aneurysm, False | 1 | 2012 | 102 | 0.360 |
Why?
|
| Congenital Abnormalities | 1 | 2014 | 254 | 0.360 |
Why?
|
| Venous Thromboembolism | 1 | 2013 | 160 | 0.360 |
Why?
|
| Vascular Diseases | 1 | 2012 | 164 | 0.360 |
Why?
|
| Surgeons | 1 | 2015 | 249 | 0.360 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 357 | 0.350 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 373 | 0.350 |
Why?
|
| Registries | 7 | 2024 | 1398 | 0.350 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 623 | 0.340 |
Why?
|
| Middle Cerebral Artery | 3 | 2021 | 109 | 0.340 |
Why?
|
| Delivery of Health Care | 1 | 2014 | 605 | 0.300 |
Why?
|
| Adult | 18 | 2023 | 29100 | 0.300 |
Why?
|
| Subarachnoid Hemorrhage | 2 | 2022 | 73 | 0.290 |
Why?
|
| Angiography | 2 | 2020 | 215 | 0.270 |
Why?
|
| Anesthesia, General | 2 | 2024 | 112 | 0.260 |
Why?
|
| Blood Vessel Prosthesis | 3 | 2020 | 535 | 0.250 |
Why?
|
| Recovery of Function | 2 | 2024 | 437 | 0.230 |
Why?
|
| Radiosurgery | 2 | 2016 | 106 | 0.230 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2024 | 32 | 0.230 |
Why?
|
| Reperfusion | 2 | 2020 | 25 | 0.230 |
Why?
|
| Carotid Artery, Internal | 3 | 2024 | 68 | 0.210 |
Why?
|
| Skull | 3 | 2023 | 141 | 0.210 |
Why?
|
| Blood Coagulation Disorders | 1 | 2024 | 99 | 0.210 |
Why?
|
| Moyamoya Disease | 1 | 2023 | 38 | 0.210 |
Why?
|
| Vasospasm, Intracranial | 1 | 2022 | 18 | 0.200 |
Why?
|
| Balloon Embolectomy | 2 | 2018 | 2 | 0.200 |
Why?
|
| Drug-Eluting Stents | 1 | 2023 | 55 | 0.200 |
Why?
|
| Fetal Stem Cells | 2 | 2012 | 5 | 0.200 |
Why?
|
| Intracranial Arteriosclerosis | 1 | 2021 | 9 | 0.190 |
Why?
|
| Maternal-Fetal Exchange | 2 | 2012 | 80 | 0.190 |
Why?
|
| Urinary Retention | 1 | 2021 | 18 | 0.190 |
Why?
|
| Radiology, Interventional | 1 | 2021 | 28 | 0.190 |
Why?
|
| Central Nervous System Vascular Malformations | 1 | 2021 | 18 | 0.190 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2022 | 127 | 0.190 |
Why?
|
| Ischemic Attack, Transient | 1 | 2021 | 55 | 0.190 |
Why?
|
| Pregnancy Complications, Cardiovascular | 2 | 2012 | 104 | 0.180 |
Why?
|
| Temporal Arteries | 1 | 2021 | 41 | 0.180 |
Why?
|
| New York City | 4 | 2021 | 58 | 0.180 |
Why?
|
| Pandemics | 4 | 2021 | 1099 | 0.180 |
Why?
|
| Time-to-Treatment | 4 | 2024 | 186 | 0.180 |
Why?
|
| Brain Infarction | 1 | 2020 | 30 | 0.180 |
Why?
|
| Hemangioma, Cavernous, Central Nervous System | 1 | 2020 | 17 | 0.180 |
Why?
|
| Pons | 1 | 2020 | 32 | 0.180 |
Why?
|
| Comprehensive Health Care | 1 | 2020 | 18 | 0.170 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2020 | 31 | 0.170 |
Why?
|
| Carotid Stenosis | 1 | 2021 | 133 | 0.170 |
Why?
|
| Fibrinolytic Agents | 1 | 2022 | 198 | 0.170 |
Why?
|
| Brain Neoplasms | 2 | 2022 | 1236 | 0.170 |
Why?
|
| Skull Base | 2 | 2020 | 54 | 0.170 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 41 | 0.170 |
Why?
|
| Empirical Research | 1 | 2019 | 9 | 0.170 |
Why?
|
| Spinal Cord Diseases | 1 | 2020 | 40 | 0.170 |
Why?
|
| Arteriovenous Malformations | 1 | 2020 | 46 | 0.170 |
Why?
|
| Arteriovenous Fistula | 1 | 2020 | 56 | 0.160 |
Why?
|
| Neoplasms | 1 | 2014 | 2758 | 0.160 |
Why?
|
| Glioblastoma | 1 | 2022 | 334 | 0.160 |
Why?
|
| Cerebrovascular Disorders | 1 | 2019 | 117 | 0.160 |
Why?
|
| Catheters | 3 | 2024 | 89 | 0.160 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2020 | 123 | 0.160 |
Why?
|
| Hyperglycemia | 1 | 2020 | 222 | 0.160 |
Why?
|
| Thrombolytic Therapy | 1 | 2020 | 204 | 0.150 |
Why?
|
| Biomechanical Phenomena | 2 | 2018 | 245 | 0.150 |
Why?
|
| Spinal Diseases | 1 | 2018 | 46 | 0.150 |
Why?
|
| Quality Indicators, Health Care | 1 | 2020 | 216 | 0.150 |
Why?
|
| Glioma | 1 | 2022 | 496 | 0.150 |
Why?
|
| Combined Modality Therapy | 2 | 2024 | 1239 | 0.150 |
Why?
|
| Lumbar Vertebrae | 1 | 2018 | 109 | 0.140 |
Why?
|
| Confidence Intervals | 2 | 2014 | 279 | 0.140 |
Why?
|
| Time Factors | 5 | 2024 | 6222 | 0.140 |
Why?
|
| Neuroendoscopy | 1 | 2016 | 26 | 0.130 |
Why?
|
| Epidermal Cyst | 1 | 2016 | 19 | 0.130 |
Why?
|
| Nervous System Neoplasms | 1 | 2016 | 11 | 0.130 |
Why?
|
| Intracranial Arteriovenous Malformations | 1 | 2016 | 28 | 0.130 |
Why?
|
| Blood Glucose | 1 | 2020 | 1123 | 0.130 |
Why?
|
| Finite Element Analysis | 1 | 2016 | 28 | 0.130 |
Why?
|
| Dermoid Cyst | 1 | 2016 | 34 | 0.130 |
Why?
|
| Epilepsy | 2 | 2016 | 858 | 0.130 |
Why?
|
| Health Personnel | 1 | 2020 | 492 | 0.120 |
Why?
|
| Carotid-Cavernous Sinus Fistula | 1 | 2015 | 9 | 0.120 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 1084 | 0.120 |
Why?
|
| Printing, Three-Dimensional | 1 | 2016 | 68 | 0.120 |
Why?
|
| Models, Anatomic | 1 | 2016 | 98 | 0.120 |
Why?
|
| Vascular Access Devices | 1 | 2015 | 35 | 0.120 |
Why?
|
| Case-Control Studies | 1 | 2022 | 3239 | 0.120 |
Why?
|
| Tuberous Sclerosis | 1 | 2016 | 121 | 0.120 |
Why?
|
| Quality Improvement | 1 | 2020 | 625 | 0.120 |
Why?
|
| Young Adult | 5 | 2016 | 8868 | 0.120 |
Why?
|
| Vascular Patency | 1 | 2015 | 204 | 0.110 |
Why?
|
| Thrombosis | 1 | 2018 | 518 | 0.110 |
Why?
|
| Patients | 1 | 2015 | 121 | 0.110 |
Why?
|
| Computer-Assisted Instruction | 1 | 2014 | 51 | 0.110 |
Why?
|
| Intention to Treat Analysis | 2 | 2024 | 58 | 0.110 |
Why?
|
| Hydrocephalus | 1 | 2016 | 242 | 0.110 |
Why?
|
| Cadaver | 1 | 2013 | 129 | 0.110 |
Why?
|
| Physician's Role | 1 | 2015 | 165 | 0.110 |
Why?
|
| Osteoarthritis, Spine | 1 | 2012 | 2 | 0.100 |
Why?
|
| Data Collection | 1 | 2015 | 383 | 0.100 |
Why?
|
| Sex Distribution | 1 | 2013 | 294 | 0.100 |
Why?
|
| Age Distribution | 1 | 2013 | 410 | 0.100 |
Why?
|
| Alberta | 2 | 2023 | 44 | 0.100 |
Why?
|
| Braces | 1 | 2012 | 14 | 0.100 |
Why?
|
| Arachnoid Cysts | 1 | 2012 | 8 | 0.100 |
Why?
|
| Coronary Artery Disease | 1 | 2018 | 750 | 0.100 |
Why?
|
| Thoracic Vertebrae | 1 | 2012 | 66 | 0.100 |
Why?
|
| Radiography | 1 | 2014 | 822 | 0.100 |
Why?
|
| Hospitalization | 2 | 2020 | 1739 | 0.100 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2016 | 421 | 0.100 |
Why?
|
| Terminology as Topic | 1 | 2013 | 228 | 0.100 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2014 | 361 | 0.100 |
Why?
|
| Pilot Projects | 1 | 2016 | 1389 | 0.100 |
Why?
|
| Preoperative Care | 1 | 2014 | 348 | 0.090 |
Why?
|
| Pain | 1 | 2015 | 470 | 0.090 |
Why?
|
| Hypothalamic Diseases | 1 | 2012 | 37 | 0.090 |
Why?
|
| Hamartoma | 1 | 2012 | 52 | 0.090 |
Why?
|
| Wounds and Injuries | 1 | 2015 | 364 | 0.090 |
Why?
|
| Risk | 1 | 2013 | 747 | 0.090 |
Why?
|
| Stem Cell Transplantation | 1 | 2012 | 238 | 0.090 |
Why?
|
| Vagus Nerve Stimulation | 1 | 2011 | 52 | 0.090 |
Why?
|
| Animals | 5 | 2024 | 33847 | 0.090 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 2854 | 0.080 |
Why?
|
| Abnormalities, Multiple | 1 | 2016 | 962 | 0.080 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 643 | 0.080 |
Why?
|
| Education, Medical, Graduate | 1 | 2014 | 503 | 0.080 |
Why?
|
| Myocardial Ischemia | 1 | 2012 | 332 | 0.080 |
Why?
|
| Adolescent | 4 | 2016 | 19133 | 0.080 |
Why?
|
| Cell Movement | 1 | 2011 | 831 | 0.070 |
Why?
|
| Prevalence | 1 | 2013 | 2409 | 0.070 |
Why?
|
| Myocardium | 1 | 2011 | 986 | 0.070 |
Why?
|
| Cerebral Angiography | 2 | 2018 | 102 | 0.070 |
Why?
|
| Child | 6 | 2016 | 24259 | 0.060 |
Why?
|
| Infarction, Anterior Cerebral Artery | 1 | 2024 | 2 | 0.060 |
Why?
|
| Vertebrobasilar Insufficiency | 1 | 2024 | 5 | 0.060 |
Why?
|
| Myocardial Infarction | 1 | 2011 | 1003 | 0.060 |
Why?
|
| Cell Differentiation | 1 | 2011 | 1912 | 0.060 |
Why?
|
| Internship and Residency | 1 | 2014 | 1160 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2024 | 335 | 0.050 |
Why?
|
| Polymethyl Methacrylate | 1 | 2023 | 24 | 0.050 |
Why?
|
| United States | 2 | 2020 | 10652 | 0.050 |
Why?
|
| Cerebral Infarction | 1 | 2023 | 46 | 0.050 |
Why?
|
| Anterior Cerebral Artery | 1 | 2022 | 8 | 0.050 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2022 | 30 | 0.050 |
Why?
|
| Dilatation | 1 | 2022 | 68 | 0.050 |
Why?
|
| Intracranial Hemorrhages | 1 | 2022 | 73 | 0.050 |
Why?
|
| Retreatment | 1 | 2022 | 88 | 0.050 |
Why?
|
| Walruses | 1 | 2021 | 1 | 0.050 |
Why?
|
| Paraparesis | 1 | 2021 | 11 | 0.050 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2024 | 257 | 0.050 |
Why?
|
| Postoperative Complications | 1 | 2014 | 3020 | 0.050 |
Why?
|
| Disease Models, Animal | 1 | 2012 | 4296 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2023 | 6030 | 0.050 |
Why?
|
| Biomarkers | 2 | 2020 | 2952 | 0.050 |
Why?
|
| Carotid Artery, Common | 1 | 2021 | 73 | 0.050 |
Why?
|
| Vasodilator Agents | 1 | 2022 | 204 | 0.050 |
Why?
|
| Cranial Fossa, Posterior | 1 | 2020 | 14 | 0.040 |
Why?
|
| Constipation | 1 | 2021 | 113 | 0.040 |
Why?
|
| Green Fluorescent Proteins | 2 | 2012 | 393 | 0.040 |
Why?
|
| Cerebral Small Vessel Diseases | 1 | 2020 | 10 | 0.040 |
Why?
|
| Blood Sedimentation | 1 | 2020 | 28 | 0.040 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 35 | 0.040 |
Why?
|
| Causality | 1 | 2020 | 83 | 0.040 |
Why?
|
| Troponin | 1 | 2020 | 71 | 0.040 |
Why?
|
| Radial Artery | 1 | 2020 | 26 | 0.040 |
Why?
|
| Prone Position | 1 | 2020 | 31 | 0.040 |
Why?
|
| Thrombophilia | 1 | 2020 | 41 | 0.040 |
Why?
|
| Critical Pathways | 1 | 2020 | 68 | 0.040 |
Why?
|
| Workflow | 1 | 2020 | 114 | 0.040 |
Why?
|
| Operating Rooms | 1 | 2020 | 69 | 0.040 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 54 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2021 | 3549 | 0.040 |
Why?
|
| Patient Positioning | 1 | 2020 | 53 | 0.040 |
Why?
|
| Monitoring, Intraoperative | 1 | 2020 | 128 | 0.040 |
Why?
|
| Patient Admission | 1 | 2020 | 184 | 0.040 |
Why?
|
| Aphasia | 1 | 2018 | 14 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2021 | 754 | 0.040 |
Why?
|
| Endoscopy | 1 | 2020 | 282 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2023 | 942 | 0.040 |
Why?
|
| Range of Motion, Articular | 1 | 2018 | 73 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 5056 | 0.040 |
Why?
|
| Neuroimaging | 1 | 2020 | 332 | 0.040 |
Why?
|
| Recurrence | 1 | 2020 | 1418 | 0.030 |
Why?
|
| Brain | 2 | 2022 | 2966 | 0.030 |
Why?
|
| Risk Factors | 2 | 2020 | 10035 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2020 | 547 | 0.030 |
Why?
|
| Disease Progression | 1 | 2022 | 2030 | 0.030 |
Why?
|
| Survival Rate | 1 | 2020 | 2002 | 0.030 |
Why?
|
| Comorbidity | 1 | 2020 | 1497 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 2016 | 121 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2024 | 4701 | 0.030 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2015 | 95 | 0.030 |
Why?
|
| Cerebral Arteries | 1 | 2015 | 79 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 1878 | 0.030 |
Why?
|
| Zygapophyseal Joint | 1 | 2012 | 4 | 0.030 |
Why?
|
| Neck Pain | 1 | 2012 | 19 | 0.030 |
Why?
|
| Incidence | 1 | 2020 | 3053 | 0.030 |
Why?
|
| CDX2 Transcription Factor | 1 | 2011 | 8 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2012 | 458 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2012 | 228 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2011 | 312 | 0.020 |
Why?
|
| Headache | 1 | 2012 | 108 | 0.020 |
Why?
|
| Infant | 2 | 2016 | 12376 | 0.020 |
Why?
|
| Calcinosis | 1 | 2012 | 170 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2016 | 13918 | 0.020 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2011 | 239 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2011 | 967 | 0.020 |
Why?
|
| Vision Disorders | 1 | 2012 | 210 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2012 | 803 | 0.020 |
Why?
|
| Models, Animal | 1 | 2011 | 466 | 0.020 |
Why?
|
| Pregnancy | 2 | 2012 | 7129 | 0.020 |
Why?
|
| Reoperation | 1 | 2012 | 819 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2011 | 516 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2011 | 543 | 0.020 |
Why?
|
| Biopsy | 1 | 2012 | 1236 | 0.020 |
Why?
|
| Anticonvulsants | 1 | 2011 | 376 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2011 | 1315 | 0.020 |
Why?
|
| Myocytes, Cardiac | 1 | 2011 | 619 | 0.020 |
Why?
|
| Electroencephalography | 1 | 2011 | 857 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2011 | 2397 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2011 | 3046 | 0.020 |
Why?
|
| Mice | 2 | 2012 | 17552 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2016 | 8114 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2012 | 4367 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2011 | 2586 | 0.010 |
Why?
|